---
layout: post
title: "中国药企入围MPP默沙东口服新冠药仿制协议名单，香港医药ETF开盘上涨1%"
date: 2022-01-21 09:36:23 +0800
categories: tiantianjijinwang
tags: 天天基金网新闻
---
<!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.513700" data-code="513700|1|1" data-code2="513700|1|9|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.513700&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 513700_0" data-code="K 513700|1|1" data-code2="K 513700|1|9|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>中国药企入围了协议名单，复星医药、博瑞医药、石家庄龙泽制药与上海迪赛诺获许可同时生产Molnupiravir的原料药和成品药，维亚生物旗下朗华制药则获许生产Molnupiravir的原料药。香港医药ETF(513700)开盘上涨1%。</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201212256104496>

[返回天天基金网新闻](//finews.withounder.com/category/tiantianjijinwang.html)｜[返回首页](//finews.withounder.com/)